October 26, 2019
Impella RP use results in 72% patient survival and 88% native heart recovery
DETROIT–(BUSINESS WIRE)–Please replace the caption for release dated October 25, 2019 with the accompanying corrected caption.
Pharmaceuticals, Biotechnology and Life Sciences
Author: BusinessWire
October 25, 2019
Colorado BioScience Association welcomes new directors
Four life sciences leaders bring deep expertise to support CBSA members, as they join as new members of the Board…
October 25, 2019
FDA Post Approval Study shows timely identification of right heart failure and early use of Impella RP leads to higher survival
FDA post approval study shows timely identification of right heart failure and early use Abiomed’s ImMpella RP leads to higher…
October 24, 2019
Spectrum Pharmaceuticals submits updated BLA to the USFDA for Rolontis
Spectrum Pharmaceuticals has submitted updated BLA to the USFDA, for Rolontis, based on two large pivotal randomized controlled studies that…
October 24, 2019
NOXXON without revenues H1 2019, net loss down to €1.9M, from €4.0M in H1 2018
BERLIN–(BUSINESS WIRE)–Regulatory News: NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by…
October 24, 2019
Xyphos Biosciences, Gladstone Institutes show convertibleCAR cells and bispecific broadly neutralizing antibodies reduce latent HIV reservoir
Xyphos Biosciences, Gladstone Institutes show convertibleCAR cells and bispecific broadly neutralizing antibodies reduce latent HIV reservoir.
October 24, 2019
Tarveda Therapeutics preclinical studies of treatment for certain lung cancer shows PEN-221 allows deep tumor penetration
Tarveda Therapeutics said in a PR Friday that PEN-221 miniature drug conjugate allow for deep tumor penetration, while limiting plasma…
October 24, 2019
Apex Benefits hosts high-cost medications event to feature Lilly, Cigna and Swiss Re Executives
INDIANAPOLIS–(BUSINESS WIRE)–Business professionals are invited to join Apex Benefits and global pharmaceutical and health industry leaders for “A Prescription for…
October 24, 2019
Velan, Progenics about Lantheus transaction
Velan Capital has issued a statement in which said Progenics has again resorted to false information and misleading Innuendo in seemingly desperate attempt to avoid accountability and deprive stockholders of chance to realize company’s full value.
October 24, 2019
European Commission approves Opdivo for treatment of certain patients with melanoma
PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #BMS—Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) flat…